HK1201280A1 - Anti-vegf antibody -vegf - Google Patents

Anti-vegf antibody -vegf

Info

Publication number
HK1201280A1
HK1201280A1 HK15101772.5A HK15101772A HK1201280A1 HK 1201280 A1 HK1201280 A1 HK 1201280A1 HK 15101772 A HK15101772 A HK 15101772A HK 1201280 A1 HK1201280 A1 HK 1201280A1
Authority
HK
Hong Kong
Prior art keywords
vegf
antibody
vegf antibody
Prior art date
Application number
HK15101772.5A
Other languages
English (en)
Chinese (zh)
Inventor
柯耀煌
朱偉民
余國良
Original Assignee
Epitomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitomics Inc filed Critical Epitomics Inc
Publication of HK1201280A1 publication Critical patent/HK1201280A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK15101772.5A 2008-03-26 2015-02-17 Anti-vegf antibody -vegf HK1201280A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3971908P 2008-03-26 2008-03-26

Publications (1)

Publication Number Publication Date
HK1201280A1 true HK1201280A1 (en) 2015-08-28

Family

ID=41114205

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101772.5A HK1201280A1 (en) 2008-03-26 2015-02-17 Anti-vegf antibody -vegf

Country Status (10)

Country Link
US (2) US7803371B2 (it)
EP (1) EP2259795B1 (it)
JP (2) JP5823858B2 (it)
KR (1) KR101581244B1 (it)
CN (2) CN103992405B (it)
AU (1) AU2008353479B2 (it)
BR (1) BRPI0822556B1 (it)
CA (3) CA2981887C (it)
HK (1) HK1201280A1 (it)
WO (1) WO2009120178A1 (it)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3216803B1 (en) * 2008-06-25 2020-03-11 Novartis Ag Stable and soluble antibodies inhibiting vegf
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
US20120207673A1 (en) * 2009-10-23 2012-08-16 Daniel Christ Modified Variable Domain Molecules And Methods For Producing And Using Same
US8753634B2 (en) * 2011-03-03 2014-06-17 Apexigen, Inc. Anti-IL-6 receptor antibodies and methods of use
CN104650229A (zh) * 2011-11-02 2015-05-27 埃派斯进有限公司 抗-kdr抗体和使用方法
CN103417965B (zh) * 2012-05-17 2018-04-13 江苏先声药业有限公司 一种含有抗vegf抗体的药物组合物
CN103417964A (zh) * 2012-05-17 2013-12-04 江苏先声药物研究有限公司 一种抗vegf抗体的用途
NZ710658A (en) 2013-02-18 2019-12-20 Vegenics Pty Ltd Ligand binding molecules and uses thereof
KR20150132581A (ko) * 2013-12-31 2015-11-25 재단법인 생물기술개발중심 항-vegf 항체 및 그것의 용도
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
JP2018511300A (ja) * 2015-01-16 2018-04-26 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 抗糖タンパク質抗体及びその使用
PE20180499A1 (es) * 2015-07-06 2018-03-09 Ucb Biopharma Sprl Anticuerpos de union a tau
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
IL260323B1 (en) 2015-12-30 2024-09-01 Kodiak Sciences Inc Antibodies and their conjugates
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US20230027475A1 (en) * 2019-09-13 2023-01-26 adMare Therapeutics Society Anti-oncolytic virus antigen antibodies and methods of using same
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN118344476A (zh) * 2024-05-16 2024-07-16 武汉爱博泰克生物科技有限公司 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342221B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
CN1299833A (zh) * 1999-12-30 2001-06-20 华西医科大学口腔医学研究所 抗人血管内皮生长因子单链抗体及其制备方法
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
AU2003264009A1 (en) * 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
CN100415765C (zh) * 2003-08-07 2008-09-03 宜康公司 兔单克隆抗体的人源化方法
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
KR102007492B1 (ko) * 2008-06-25 2019-08-05 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物

Also Published As

Publication number Publication date
CN103992405B (zh) 2016-08-17
BRPI0822556B1 (pt) 2022-03-03
CN103992405A (zh) 2014-08-20
WO2009120178A1 (en) 2009-10-01
CA3053675A1 (en) 2009-10-01
CA2719400A1 (en) 2009-10-01
CN102065888A (zh) 2011-05-18
CA2719400C (en) 2017-11-14
CA2981887C (en) 2019-09-03
US20110008367A1 (en) 2011-01-13
JP2014205674A (ja) 2014-10-30
CN102065888B (zh) 2014-03-26
EP2259795A1 (en) 2010-12-15
US7803371B2 (en) 2010-09-28
AU2008353479B2 (en) 2014-02-20
US8088375B2 (en) 2012-01-03
CA2981887A1 (en) 2009-10-01
KR101581244B1 (ko) 2015-12-31
KR20100132983A (ko) 2010-12-20
EP2259795B1 (en) 2016-04-06
JP5823858B2 (ja) 2015-11-25
BRPI0822556A2 (pt) 2020-08-18
EP2259795A4 (en) 2012-06-06
JP2011517447A (ja) 2011-06-09
AU2008353479A1 (en) 2009-10-01
US20090246190A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
HK1208478A1 (en) Anti-vegf antibodies -vegf
HK1201280A1 (en) Anti-vegf antibody -vegf
HK1199265A1 (en) Bispecific anti-vegf/anti-ang-2 antibodies -vegf/-ang-2
EP2280616A4 (en) BODY FOR BABY
IL208990A0 (en) Novel phenylimidazopyrazines
EP2257170A4 (en) TÉTRAHYDROFUROPYRIDONES
EP2285758A4 (en) DISPOSABLE PACKAGING FOR FERTILIZER-PESTICIDE
EP2313147A4 (en) crimping
GB0801600D0 (en) Microtrench
EP2233305A4 (en) GRAPHIC PRINTER
EP2285375A4 (en) SPIROAZAINDOLE
GB0801589D0 (en) Mollusicide
GB0800389D0 (en) Gileo hang-it
GB0800161D0 (en) Rota-board
AU3935P (en) DPV308 Dianella prunina
AU3972P (en) Tobruk xTriticosecale
AU3977P (en) PARV01 Myoporum parvifolium
AU4098P (en) NPW2 Dianella tasmanica
AU2008371V (en) Berbee Dianella tasmanica
GB0800902D0 (en) Gumtray
AU322905S (en) LED-Luminaire
AU2008315V (en) DT5001 Dianella tasmanica
AU2008306V (en) LND01 Lomandra confertifolia
GB0800104D0 (en) Dissolve-a-bottle
AU2008295V (en) Canobolas xTriticosecale